Cart (0 Items)
Your cart is currently empty.
View ProductsBrand | ProteoGenix |
---|---|
Product type | Elisa assay kits |
Size | 96T |
Product name | Oleclumab ELISA Kit |
---|---|
Delivery condition | Blue ice (+4°) |
Storage condition | The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition. |
Brand | ProteoGenix |
Size | 96T |
Reference | KPTX207 |
Note | For research use only. |
Sample type | Plasma, Serum |
Immunogen | Oleclumab |
The Oleclumab ELISA Kit is a highly sensitive and specific assay for the detection and quantification of Oleclumab in biological samples. This kit is designed for research use only and is not intended for diagnostic purposes.
Oleclumab is a monoclonal antibody that specifically targets the immune checkpoint protein, programmed death-ligand 1 (PD-L1). It is a fully human IgG1 antibody with a molecular weight of approximately 150 kDa. The antibody consists of two heavy chains and two light chains, each containing a variable region and a constant region. The variable region is responsible for binding to PD-L1, while the constant region determines the effector functions of the antibody.
The Oleclumab ELISA Kit uses a sandwich enzyme-linked immunosorbent assay (ELISA) format, where the target protein (Oleclumab) is captured by a specific antibody coated on the microplate. The captured Oleclumab is then detected by a second antibody that is conjugated with an enzyme (horseradish peroxidase) and produces a colorimetric signal when a substrate is added. The intensity of the signal is directly proportional to the amount of Oleclumab present in the sample.
Oleclumab binds to PD-L1 on the surface of cancer cells and blocks the interaction between PD-L1 and its receptor, programmed cell death protein 1 (PD-1), on T cells. This interaction is known to inhibit T cell activation and proliferation, leading to immune evasion by cancer cells. By blocking this interaction, Oleclumab enhances the anti-tumor immune response and promotes the killing of cancer cells by T cells.
In addition to blocking the PD-L1/PD-1 interaction, Oleclumab also has other immune-modulating activities. It has been shown to increase the production of pro-inflammatory cytokines and chemokines, as well as promote the activation and recruitment of other immune cells such as natural killer cells and dendritic cells. These activities contribute to the overall anti-tumor effect of Oleclumab.
The Oleclumab ELISA Kit has a wide range of applications in the field of cancer research. It can be used to measure the concentration of Oleclumab in various biological samples, including serum, plasma, and cell culture supernatant. This allows for the monitoring of Oleclumab levels in patients receiving treatment with this antibody.
The kit can also be used to screen for PD-L1 expression in cancer cells and evaluate the effectiveness of Oleclumab in blocking the PD-L1/PD-1 interaction. This information can help in patient selection for Oleclumab therapy and monitoring of treatment response.
Furthermore, the Oleclumab ELISA Kit can be used to study the pharmacokinetics of Oleclumab, such as its absorption, distribution, metabolism, and excretion in the body. This information is crucial for optimizing the dosing regimen and ensuring the safety and efficacy of Oleclumab in clinical trials.
In conclusion, the Oleclumab ELISA Kit is a valuable tool for studying the structure, activity, and application of Oleclumab in cancer research. Its high sensitivity and specificity make it a reliable method for measuring Oleclumab levels and evaluating its therapeutic potential. With the increasing interest in immune checkpoint inhibitors as cancer therapeutics, the Oleclumab ELISA Kit will continue to play a crucial role in advancing our understanding of this promising antibody.
Send us a message from the form below
Reviews
There are no reviews yet.